MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1128/aac.01105-25

Медицинская библиотека · Antimicrobial agents and chemotherapy · 2026

Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection.

Wang Jia, Paroha Ruchi, Sha Jian, Verma Atul K, Neil Blake H, Kilgore Paul B, Hendrix Emily K, Brown-Elliott Barbara, Chopra Ashok K, Lee Sunhee

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Mycobacterium abscessus, a rapidly growing nontuberculous mycobacterium, causes chronic pulmonary infections that are difficult to treat due to extensive intrinsic drug resistance. Through high-content screening of 786 FDA-approved drugs against intracellular M. abscessus in human THP-1 macrophages, we identified naftifine, an antifungal allylamine, as a novel antimycobacterial agent with dual-acting therapeutic mechanisms. Naftifine demonstrated potent activity against reference strains and multidrug-resistant clinical isolates. It showed enhanced efficacy in intracellular environments compared to axenic culture, indicating significant host-directed effects. Mechanistic investigations revealed that naftifine operates through a unique dual mechanism. It directly targets bacteria by inhibiting MmpL3 (MAB_4508), the essential mycolic acid transporter, and modulates host immunity through autophagy activation via the mTOR pathway suppression. Whole-genome sequencing of spontaneous naftifine-resistant mutants identified point mutations (S302T and V299G) in MmpL3. Complementation studies confirmed MmpL3 as the primary molecular target. Cross-resistance analysis with other MmpL3 inhibitors (BM212 and AU1235) validated this target identification. Notably, naftifine represents the first MmpL3 inhibitor demonstrated to induce autophagy, distinguishing it from other MmpL3-targeting compounds. Naftifine-induced autophagy enhanced macrophage-mediated bacterial clearance and reduced infection-associated necrosis, improving host cell survival. In vivo studies demonstrated a significant reduction of pulmonary and splenic bacterial burden with reduced lung inflammation. Furthermore, naftifine exhibited synergistic activity with β-lactam antibiotics without antagonizing other clinically used antibiotics. This is the first report demonstrating the unique combination of MmpL3 inhibition and autophagy induction by a single compound against M. abscessus, establishing naftifine as a promising dual-action therapeutic candidate for treating multidrug-resistant infections.

Для цитирования: Wang Jia, Paroha Ruchi, Sha Jian, Verma Atul K, Neil Blake H, Kilgore Paul B, Hendrix Emily K, Brown-Elliott Barbara, Chopra Ashok K, Lee Sunhee. Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection.. Antimicrobial agents and chemotherapy. 2026. DOI: 10.1128/aac.01105-25.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.